Gilead Sciences (LTS:0QYQ) Additional Paid-In Capital : $6,500 Mil(As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences Additional Paid-In Capital?

Gilead Sciences's quarterly additional paid-in capital increased from Jun. 2023 ($6,008 Mil) to Sep. 2023 ($6,279 Mil) and increased from Sep. 2023 ($6,279 Mil) to Dec. 2023 ($6,500 Mil).

Gilead Sciences's annual additional paid-in capital increased from Dec. 2021 ($4,661 Mil) to Dec. 2022 ($5,550 Mil) and increased from Dec. 2022 ($5,550 Mil) to Dec. 2023 ($6,500 Mil).

Gilead Sciences Additional Paid-In Capital Historical Data

The historical data trend for Gilead Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Additional Paid-In Capital Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,051.00

3,880.00

4,661.00

5,550.00

6,500.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															5,550.00	5,793.00	6,008.00	6,279.00	6,500.00

Gilead Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Gilead Sciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (LTS:0QYQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (LTS:0QYQ) Headlines

No Headlines